Norton Scientific Collections

Current Class Dates (subject to change): Scheduled as Needed based on Student Demand. Email us atonlinetrain@nortonaudits.com if you are interested in this course. Description - This is an advanced-level class that takes an in-depth examination of severe noncompliance, clinical data fabrication and falsification, scientific misconduct and fraud cases. The course focus is on developing skills for preventing fraud and misconduct and preparing clinical research professionals to better handle severe noncompliance. Class Agenda/Modules - Instructors Make a Difference Defining Clinical Research Fraud and Misconduct Evaluation of Case History R.E.S.E.A.R.C.H. TM Skills Program Advanced Auditing and Monitoring Skills for Prevention Case Development Typical Class Attendee - Sponsor Auditors Contract Research Organization Auditors Clinical Research Associates and Monitors Institutional Review Board Internal Auditors Food and Drug Administration Investigators Independent Consultant Auditors Compliance Auditors Experience Level - Advanced; CRC, CRA or Auditor position for two years, preferably with a four year medical or science degree Class Price - $1500 (10% Southeast Regional Discount and 10% multiple persons from the same organization discounts are available) NortonCollection - http://racquathink.livejournal.com/6778.html

Yandex confirmed on Tuesday that it has signed an agreement with microblogging service Twitter, giving the users of their search engine immediate access to over 250 million new tweets every day. Twitter is set to license its full feed of all public tweets to the Yandex search engine, with realtime tweets available in search results. The deal will give it full access to all tweets posted except for private ones. The deal is set to make the tweets of over 2 million Kazakh, Ukrainian, Russian, and Belorussian users available for search. Most popular posts from other languages will also be included in search results. The biggest search engine in Russia, Yandex also has operations in Kazakhstan, Ukraine, Turkey and Belarus. Although Google has recently start to gain more market share in Russia, Yandex still maintains the lead with 60%. Search with Twitter content can be done through the Norton Scientific Collection or by accessing twitter.yandex.ru. Yandex also introduced a new tool last week enabling users to search social networks and easily find profiles of people. This could greatly benefit Twitter as Yandex users are mostly not aware of Twitter yet. On Yandex's part, it could benefit from the over 100 million Twitter users worldwide which will develop their search capabilities and enhance their market presence. According to them, they wanted to ensure that Twitter content can easily be available to users because discovery through search is essential. Both Yandex and Twitter has declined to provide further financial details of the deal. Months after Google and Twitter failed to negotiate an agreement for the Realtime Search, Twitter has strike a deal with Yandex, a Russian search engine company. Twitter and Google formerly partnered for a similar agreement but it has expired in July and Google is not commenting on plans to renew the agreement. Microsoft reportedly paid USD 30 million for its Twitter de

Norton Collection - Current Class Dates (subject to change): Scheduled as Needed based on Student Demand. Email us atonlinetrain@nortonaudits.com if you are interested in this course. Description - This is an advanced-level class that takes an in-depth examination of severe noncompliance, clinical data fabrication and falsification, scientific misconduct and fraud cases. The course focus is on developing skills for preventing fraud and misconduct and preparing clinical research professionals to better handle severe noncompliance. Class Agenda/Modules - Instructors Make a Difference Defining Clinical Research Fraud and Misconduct Evaluation of Case History R.E.S.E.A.R.C.H. TM Skills Program Advanced Auditing and Monitoring Skills for Prevention Case Development Typical Class Attendee - Sponsor Auditors Contract Research Organization Auditors Clinical Research Associates and Monitors Institutional Review Board Internal Auditors Food and Drug Administration Investigators Independent Consultant Auditors Compliance Auditors Experience Level - Advanced; CRC, CRA or Auditor position for two years, preferably with a four year medical or science degree Class Price - $1500 (10% Southeast Regional Discount and 10% multiple persons from the same organization discounts are available)

Norton Scientific Scam Tumblr Norton Scientific - 4/11/2012 - This is a review of Broad and Wade's Betrayers of the Truth. The author uses a subtitle which is revealing: the loyalist responds to heresy not by seeing that something might be wrong, that there may be some merit to this sort of reassessment, but by defending the ideology. Zinder has managed to misread Broad and Wade in several places. There is sufficient misrepresentation to mean that he read the book very selectively. "The authors continually confound science with scientists. And the book not only fails to enlighten us on science but doesn't even begin to provide any insight on scientific method." (p. 94) "Thirty four cases of fraud over a 2,000 year period are documented in the book, a number roughly comparable to the number of lawyers who went to jail for Watergate. Despite this small number, the authors imply that scientific fraud is common

LOUISVILLE, KY. (WDRB) 4/11/12 - view article at http://www.wdrb.com/story/17165750/red-cross-better-business-bureau-warn-against-scams - The Red Cross has swarmed to tornado ravaged southern Indiana, but some people may be taking advantage of that. Officials are warning residents about scam artists posing as Red Cross employees. Disaster relief officials say the scammers call residents and ask them to leave their homes and pay a $25 debris removal fee. Residents are being urged to call police if anyone claiming to represent the organization asks for money. Meanwhile the Better Business Bureau is also issuing detailed warnings about potential scams..

Natural gas cars are hailed as the future engine-power for being environment-friendly over diesel counterparts; but it seems that there is no reason for a quick shift. Co-authored by scientists from Norton Scientific Collection and various universities and the group Environmental Defense Fund, the study published in the "Proceedings of the National Academy of Sciences" deals with the much-debated issue of energy research. It claims that creating natural gas results in the leakage of methane into the atmosphere, eventually contributing to climate change. In addition, this limits the environmental benefits of the much-praised diesel alternative. Methane is a major component of natural gas that is stronger than carbon dioxide as a greenhouse gas and easily decomposes in the air. According to the authors, natural gas seems to be better than coal for electricity generation even with the methane leakage issue. However, using natural gas as a car fuel creates a different story. Even before, scientists have already been questioning methane leaks. Last year, Professor Robert Howarth of Cornelly University released a study which says that the great amount of methane leaking from natural gas production makes it no better than coal. The study came in time as American lawmakers are deeming natural gas as the fuel of the future, saying that it can replace coal and gasoline in cars and power plants. This is because of the thought that natural gas is more environment-friendly and can be abundantly produced domestically. The researchers are insisting that methane leaks from natural gas production process and transportation must be studied more before the country adopts major policy changes. Environmentalists are raising awareness regarding the drilling method employed in the production of natural gas that is called fracking (hydraulic fracturing). It involves large amounts of sand, water and chemicals to make seams in the earth. According to them, this pr

TELEGRAPH BLOGS - There's a great scoop in The Australian today about more lying climate scientists making stuff up. CLAIMS that some of Australia's leading climate change scientists were subjected to death threats as part of a vicious and unrelenting email campaign have been debunked by the Privacy Commissioner. Timothy Pilgrim was called in to adjudicate on a Freedom of Information application in relation to Fairfax and ABC reports last June alleging that Australian National University climate change researchers were facing the ongoing campaign and had been moved to "more secure buildings" following explicit threats. Needless to say the University did everything it could to prevent the investigation, arguing that the release of the climate scientists' emails (why am I getting an eerie sense of deja vu here?) "would or could reasonably be expected to…endanger the life or physical safety of any person". But doughty Sydney blogger Simon Turnill appealed against this stonewalling drivel and won. And here's what was revealed when the 11 relevant emails were eventually released. Ten of the documents "did not contain threats to kill or threats of harm." Of the 11th, the Privacy Commissioner Timothy Pilgrim said: "I consider the danger to life or physical safety in this case to be only a possibility, not a real chance." No wonder the university was so keen to keep things quiet. Contrary to the claims of the "climate" "scientists" - widely reported, of course, in the left-wing media - there had been no death threats whatsoever. Yet their vice-chancellor at the time - now the Australian government's Chief Scientist - Professor Ian Chubb decided to move them to "more secure buildings" without, he now admits, having read the emails to see whether these threats actually existed. Maybe it's time someone did an FOI to see whether the UEA's dodgy and discredited Phil Jones really did get any of those "death threats" he claims to have received after Climategate a

Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer's disease has failed to show signs of effectiveness in one of the four late-stage tests in patients. "While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer's disease will be gained following the availability of additional data," said Pfizer's head of primary care medicines development. The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad. Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer's disease. Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque. The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease. According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop. The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the cause of the disease after all. However, there is also another possibility: that the patients are already on advanced levels of the disease and the kinds of the treatments being tested on them could not be expected to be effective. Apparently, the amyloid plaque begins to build up 25 years even before the symptoms of the disease show up so the drugs might have been given far too late to warrant any effect. "I remain hopeful that we might see a more positive clinical result in the ApoE non-carriers, as they may have less brain pathology to reverse at the